Black Diamond Therapeutics (BDTX) Cash & Current Investments (2018 - 2026)

Black Diamond Therapeutics (BDTX) has 9 years of Cash & Current Investments data on file, last reported at $118.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 22.4% year-over-year to $118.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.3 million (down 22.4% YoY) and the FY2025 annual result came in at $128.7 million, up 30.51% from the prior year.
• Cash & Current Investments eased to $118.3 million in Q1 2026, from $128.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $179.7 million in Q1 2022 to a low of $89.5 million in Q2 2023.
• A 5-year average of $129.6 million and a median of $128.7 million in 2025 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 44.36% — and 2024, when it jumped 37.36%.
• Tracing BDTX's Cash & Current Investments over 5 years: stood at $122.8 million in 2022, then gained by 7.0% to $131.4 million in 2023, then retreated by 24.98% to $98.6 million in 2024, then surged by 30.51% to $128.7 million in 2025, then dropped by 8.08% to $118.3 million in 2026.
• The last three Cash & Current Investments figures came in at $118.3 million (Q1 2026), $128.7 million (Q4 2025), and $135.5 million (Q3 2025), per Business Quant data.